

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC STUDIES ONLY (TXCA=Y)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1558	144	9%	973	-584	903	-655
ERLYTX	76	19	25%	128	52	270	194
GI	476	10	2%	67	-408	101	-375
GU	450	75	17%	506	56	412	-38
GYN	57	0	0%	0	-57	0	-57
LEUK	150	9	6%	60	-89	120	-30
LUNG	524	26	5%	175	-348	211	-313
LYMPH	172	7	4%	47	-124	32	-140
MELAN	55	15	27%	101	46	98	43
MMYEL	147	11	7%	74	-72	102	-45
OTHER	0	2		13	13	49	49
SXQOL	0	1		6	6	12	12
Total	3665	319		2150	-1509	2310	-1355

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	3		20	20	3	3
BREAST	37	72	195%	486	449	376	339
CCD	0	241		1628	1628	1542	1542
GU	0	0		0	0	0	0
LEUK	69	7	10%	47	-21	19	-50
LUNG	43	52	121%	351	308	576	533
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	0		0	0	3	3
PREV	0	5		33	33	45	45
SURV	0	29		196	196	136	136
<u>SXQOL</u>	<u>878</u>	<u>1</u>	<u>0%</u>	<u>6</u>	<u>-871</u>	<u>5</u>	<u>-873</u>
Total	1172	410		2767	1597	2705	1533

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	3		20	20	3	3
BREAST	1595	216	14%	1460	-135	1279	-316
CCD	0	241		1628	1628	1542	1542
ERLYTX	76	19	25%	128	52	270	194
GI	476	10	2%	67	-408	101	-375
GU	450	75	17%	506	56	412	-38
GYN	57	0	0%	0	-57	0	-57
LEUK	219	16	7%	108	-110	139	-80
LUNG	567	78	14%	527	-39	787	220
LYMPH	225	7	3%	47	-177	32	-193
MELAN	55	15	27%	101	46	98	43
MMYEL	239	11	5%	74	-164	102	-137
OTHER	0	2		13	13	52	52
PREV	0	5		33	33	45	45
SURV	0	29		196	196	136	136
SXQOL	878	2	0%	13	-864	17	-861
Total	4837	729		4921	90	5015	178

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1012	95	9%	642	-369	594	-418
ERLYTX	76	16	21%	108	32	180	104
GI	418	7	2%	47	-370	82	-336
GU	375	51	14%	344	-30	264	-111
GYN	57	0	0%	0	-57	0	-57
LEUK	122	9	7%	60	-61	84	-38
LUNG	441	23	5%	155	-285	175	-266
LYMPH	129	6	5%	40	-88	29	-100
MELAN	55	11	20%	74	19	71	16
MMYEL	85	10	12%	67	-17	94	9
OTHER	0	2		13	13	49	49
SXQOL	0	1		6	6	12	12
Total	2770	231		1556	-1207	1634	-1136

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	3		20	20	3	3
BREAST	10	72	720%	486	476	376	366
CCD	0	183		1236	1236	1187	1187
GU	0	0		0	0	0	0
LEUK	69	7	10%	47	-21	19	-50
LUNG	30	50	167%	337	307	422	392
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	0		0	0	3	3
PREV	0	5		33	33	34	34
SURV	0	20		135	135	91	91
SXQOL	740	1	0%	6	-733	5	-735
Total	994	341		2300	1308	2140	1146

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	3		20	20	3	3
BREAST	1022	167	16%	1128	106	970	-52
CCD	0	183		1236	1236	1187	1187
ERLYTX	76	16	21%	108	32	180	104
GI	418	7	2%	47	-370	82	-336
GU	375	51	14%	344	-30	264	-111
GYN	57	0	0%	0	-57	0	-57
LEUK	191	16	8%	108	-82	103	-88
LUNG	471	73	15%	493	22	597	126
LYMPH	182	6	3%	40	-141	29	-153
MELAN	55	11	20%	74	19	71	16
MMYEL	177	10	6%	67	-109	94	-83
OTHER	0	2		13	13	52	52
PREV	0	5		33	33	34	34
SURV	0	20		135	135	91	91
SXQOL	740	2	0%	13	-726	17	-723
Total	3764	572		3859	101	3774	10

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2019 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2019 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	65	127	195%	858	793	785	720
CCD	0	241		1628	1628	1542	1542
GI	81	1	1%	6	-74	43	-38
GU	215	58	27%	392	177	272	57
LEUK	0	7		47	47	19	19
LUNG	53	0	0%	0	-53	11	-42
LYMPH	7	0	0%	0	-7	0	-7
MELAN	0	3		20	20	9	9
MMYEL	0	7		47	47	82	82
OTHER	0	2		13	13	11	11
PREV	0	5		33	33	45	45
SURV	0	29		196	196	136	136
<u>SXQOL</u>	<u>878</u>	<u>2</u>	<u>0%</u>	<u>13</u>	<u>-864</u>	<u>17</u>	<u>-861</u>
Total	1299	482		3253	1956	2972	1673

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		EA8171	ECOG-ACR			2			
		EA9161	ECOG-ACR			1			
BREAST	II	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG	13APR2017:00:00:00		6		0.7	
		S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	31	301	333	8.7	May-2019
		S1706 Breast, Inflammatory, RT +/- Olaparib	SWOG	12SEP2018:00:00:00	5	2	300	0.4	> 15 Yrs
	II-III	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG	24DEC2014:00:00:00		1		0.0	
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		85		1.8	
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		213		7.0	
		A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		78		4.7	
		B51 Breast, Regional Nodal XRT	NRG	22AUG2013:00:00:00		33		0.7	
		B55 Brst, Adj Olaparib for BRCA,TNBC	NRG	03JUL2014:00:00:00		33		0.5	
		EA1151 Brst, Tomosynthesis Mammographic Screening	ECOG-ACRIN	06JUL2017:00:00:00		324		26.0	
		NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		69		1.7	
		S1207 Brst,Adj,Endocrine+/-Everolimus	SWOG	03SEP2013:00:00:00	65	1856	1900	29.3	Mar-2019
		S1222 Brst,Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	27	380	1000	21.5	Jun-2021
	OTHER	A221405 Breast, ET interruption, Pregnancy Outcomes	ALLIANCE	15OCT2015:00:00:00		13		0.2	
		E1Z11 Brst,Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		156		0.5	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		19		0.8	
		A191402C PROS, Testing Decision Aids for Minority Men	ALLIANCE	14JUL2017:00:00:00		17		1.3	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	29	2693	3960	107.2	Jan-2020
		S1703 Met Breast, STM-monitoring v Usual Care	SWOG	16JUL2018:00:00:00	7	2	1056	0.3	> 15 Yrs
	OTHER	ACCL16N1 Guideline Consistent Treatment AYA ALL	COG	18DEC2017:00:00:00		34		5.7	
		EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer	ECOG-ACRIN	17MAY2018:00:00:00		18		2.5	
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.0	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	25	557	707	5.7	Apr-2021
	II-III	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		9		0.0	
	OTHER	EAY131 MATCH	ECOG-ACRIN	12AUG2015:00:00:00		142		4.2	
GI	II	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		15		0.0	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		4		0.0	
		EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128	ECOG-ACRIN	01FEB2017:00:00:00		1		0.2	
		EA2165 Anal, Stg II-III, Nivolumab after CMT	ECOG-ACRIN	13APR2018:00:00:00		2		0.3	
		S1613 mCRC, Adv/Met, TP vs CETIRI	SWOG	09OCT2017:00:00:00	16	18	130	1.7	Sep-2024
	III	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	ALLIANCE	12SEP2017:00:00:00		10		0.8	
		NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG	07NOV2017:00:00:00		5		0.5	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
GU	II	S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel	SWOG	03DEC2018:00:00:00	2	3	268		
		A031701 Bladder, ddGC for MIBC with DDR Tumor Alt	ALLIANCE	01AUG2018:00:00:00		1		0.2	
		EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2)	ECOG-ACRIN	08FEB2018:00:00:00		4		0.3	
		S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	34	119	148	2.5	Jan-2020
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	24	122	162	9.3	Jun-2019
	II-III	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG	30DEC2016:00:00:00		2		0.2	
		III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		4		0.2
	A031501 Bladder, MIBC/Loc Adv, Adjuv Pembro vs Obs		ALLIANCE	21SEP2017:00:00:00		25		3.0	
	EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)		ECOG-ACRIN	02FEB2017:00:00:00		26		1.8	
	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT		NRG	07JUL2011:00:00:00		92		0.8	
S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG		07FEB2017:00:00:00	24	237	969	15.8	Dec-2022	
LEUK	I	S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum	SWOG	17SEP2018:00:00:00	5	35	1273	6.7	> 15 Yrs
		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	58	49	38	1.3	Jun-2018
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00		47	44		Sep-2017 Temp Close
	II	S1712 CML, chronic phase, TKI +/- Ruxolitinib	SWOG	20JUL2018:00:00:00	7	3	84	0.5	Aug-2032
	II-III	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	SWOG	22DEC2017:00:00:00		78	1670		Temp Close
	III	A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo	ALLIANCE	01JUN2017:00:00:00		1		0.2	
		E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		106		2.3	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		26		1.7	
	LUNG	II	S1400F Non-Match: MEDI4736 + Tremelimumab	SWOG	02OCT2017:00:00:00	16	56	132	4.5
S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac			SWOG	09AUG2018:00:00:00	6	0	66	0.0	> 15 Yrs
S1900A LOH and/or BRCA: Rucaparib			SWOG	28JAN2019:00:00:00	0	0	88		
II-III		NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		4		0.0	
III		A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		48		1.3	
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		56		0.0	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACRIN	18AUG2014:00:00:00		12		0.5	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		93		4.7	
OTHER		A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		664		14.2	
		LUNGMAP NSCLC, Adv, Master	SWOG	28JAN2019:00:00:00	0	20			
PILOT	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	SWOG	03NOV2017:00:00:00	15	10	28	1.0	Jul-2020	
LYMPH	II	S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	SWOG	10AUG2017:00:00:00	18	14	150	1.3	Jul-2027
	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		6		0.0	
	EA4151 Lymph, AHCT +/-Ritux, MRD Neg	ECOG-ACRIN	29AUG2017:00:00:00		20		2.0		
MELAN	II	S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	55	241	248	3.3	Apr-2019

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	28	19	77	0.8	Nov-2024
		S1607 MELAN, Adv, T-VEC, MK-3475	SWOG	02OCT2017:00:00:00	16	12	64	1.7	Sep-2021
		S1616 MELAN, Adv, Ipilimumab ± Nivolumab	SWOG	17JUL2017:00:00:00	19	30	94	1.3	Jan-2023
		S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab	SWOG	06DEC2018:00:00:00	2	1	556		
	II-III	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		36		0.0	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACRIN	15DEC2015:00:00:00		33		1.0	
MMYEL	II	S1702 AL Amyloidosis, Relapsed, Isatuximab	SWOG	08MAR2018:00:00:00	11	20	39	2.7	Sep-2019
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		259		8.0	
OTHER	II	A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		10		0.0	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cispl	ECOG-ACRIN	29MAR2016:00:00:00		12		0.5	
		EAF151 Brain, GBM, Bev, Blood Volume	ECOG-ACRIN	14APR2017:00:00:00		2		0.0	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.0	
	II-III	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.0	
		NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev	NRG	12MAY2017:00:00:00		6		1.0	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		6		0.2	
		R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
	III	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	NRG	12APR2010:00:00:00		1		0.0	
		N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	ALLIANCE	22SEP2009:00:00:00		7		0.0	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
	OTHER	EAQ152 Communication & education in tumor profiling	ECOG-ACRIN	26SEP2016:00:00:00		14		0.3	
PREV	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.0	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	71	231	480	3.5	Jan-2025
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACRIN	30SEP2015:00:00:00		19		1.2	
		S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00	17	76	817	8.7	Mar-2026
	OTHER	EA9131 Leuk, Strategy to decrease early APL deaths	ECOG-ACRIN	16AUG2017:00:00:00		22		2.0	
		S1316 Compar. Effectiv. Trial for MBO	SWOG	09MAR2015:00:00:00	47	176	200	2.8	Oct-2019
SXQOL	III	A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		21		0.0	
		A221505 Brst, Hypofractionated Post Mast Rad	ALLIANCE	01FEB2018:00:00:00		7		0.8	
		S1600 Bladder,Radical Cystectomy Outcomes Nutrition	SWOG	21FEB2019:00:00:00	0	0	200		
		S1614 HBV in Ca Pts, TAF vs SOC	SWOG	21FEB2019:00:00:00	0	0	444		
	PILOT	A221504 NSCL, Advanced, placebo vs naloxegol	ALLIANCE	13OCT2017:00:00:00		2		0.3	

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
		Y	ALLIANCE	A221405 Breast, ET interruption, Pregnancy Outcomes	A221405	Y	
	CCD	Y	COG	ACCL16N1 Guideline Consistent Treatment AYA ALL	ACCL16N1CD	Y	
		Y	ECOG-ACRIN	EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer	EAQ162CD	Y	
	ERLYTX	Y	ECOG-ACRIN	EAY131 MATCH	EAY131	N	
	LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
	LUNG	Y	SWOG	LUNGMAP NSCLC, Adv, Master	LUNGMAP	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ECOG-ACRIN	EAQ152 Communication & education in tumor profiling	EAQ152	Y	
	SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO	S1316	Y	
		Y	ECOG-ACRIN	EA9131 Leuk, Strategy to decrease early APL deaths	EA9131	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
I-II	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	Y
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
		Y	SWOG	S1706 Breast, Inflammatory, RT +/- Olaparib	S1706	N	
		Y	NRG	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG-BR005	N	
	ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/Ipi	S1609	N	
		Y	ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	A071401	N	
	GI	Y	SWOG	S1613 mCRC, Adv/Met, TP vs CETIRI	S1613	N	
		Y	ECOG-ACRIN	EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128	EA2161	N	
		Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	EA2142	N	
		Y	ECOG-ACRIN	EA2165 Anal, Stg II-III, Nivolumab after CMT	EA2165	N	
		Y	ALLIANCE	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	A021501	N	
	GU	Y	SWOG	S1500 pRCC,Adv, Sunitinib vs MET inhib	S1500	N	
		Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	S1605	N	
		Y	ECOG-ACRIN	EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2)	EA8153	N	
		Y	ALLIANCE	A031701 Bladder, ddGC for MIBC with DDR Tumor Alt	A031701	N	
	LEUK	Y	SWOG	S1712 CML, chronic phase, TKI +/- Ruxolitinib	S1712	N	
	LUNG	Y	SWOG	S1900A LOH and/or BRCA: Rucaparib	S1900A	N	
		Y	SWOG	S1400F Non-Match: MEDI4736 + Tremelimumab	S1400F	N	
		Y	SWOG	S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac	S1701	N	
	LYMPH	Y	SWOG	S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	S1608	N	
	MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin	S1320	N	
		Y	SWOG	S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab	S1801	N	
		Y	SWOG	S1607 MELAN, Adv, T-VEC, MK-3475	S1607	N	
		Y	SWOG	S1616 MELAN, Adv, Ipilimumab ± Nivolumab	S1616	N	
		Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	S1512	N	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
	MMYEL	Y	SWOG	S1702 AL Amyloidosis, Relapsed, Isatuximab	S1702	N	
	OTHER	Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG-BN001	N	
		Y	ALLIANCE	A091401 Sarc,	A091401	N	
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
		Y	ECOG-ACRIN	EAF151 Brain, GBM, Bev, Blood Volume	EAF151	N	
PILOT	LUNG	Y	SWOG	S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	S1619	N	
	SXQOL	Y	ALLIANCE	A221504 NSCL, Advanced, placebo vs naloxegol	A221504	Y	
II-III	BREAST	Y	NRG	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG-BR002	N	
	ERLYTX	Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GU	Y	NRG	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG-GU002	N	
	LEUK	Y	SWOG	S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics	S1612	N	Y
	LUNG	Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY009 Ovar, PLD/Atezo vs PLD/Atezo/Bev vs PLD/Bev	NRG-GY009	Y	
		Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ALLIANCE	A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	A011502	Y	
		Y	ECOG-ACRIN	EA1151 Brst, Tomosynthesis Mammographic Screening	EA1151	N	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
CCD		Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	SWOG	S1703 Met Breast, STM-monitoring v Usual Care	S1703	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
		Y	ALLIANCE	A191402C PROS, Testing Decision Aids for Minority Men	A191402CD	Y	
	GI	Y	SWOG	S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel	S1815	N	
		Y	ALLIANCE	A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC	A021502	Y	
		Y	NRG	NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG-GI004	Y	
	GU	Y	SWOG	S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum	S1802	Y	
		Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y	
		Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

<u>Phase</u>	<u>Comm.</u>	<u>Int</u> <u>grp</u>	<u>Stat</u> <u>Center</u>	<u>Study</u>	<u>NCIPROTO</u>	<u>CA</u> <u>Cntrl</u>	<u>Temp</u> <u>Close</u>
		Y	ECOG-ACRIN	EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER)	EA8143	Y	
		Y	ALLIANCE	A031501 Bladder, MIBC/Loc Adv, Adjuv Pembro vs Obs	A031501	Y	
		Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y	
LEUK		Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y	
		Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N	
		Y	ALLIANCE	A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo	A041501	N	
LUNG		Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y	
		Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N	
		Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N	
		Y	ECOG-ACRIN	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N	
LYMPH		Y	ECOG-ACRIN	EA4151 Lymph, AHCT +/-Ritux, MRD Neg	EA4151	N	
		Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N	
MELAN		Y	ECOG-ACRIN	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y	
MMYEL		Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y	
OTHER		Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N	
		Y	NRG	G0263 Cerv, Stg I/IIA, adjuv RT vs chemoRT	GOG-0263	Y	
		Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y	
PREV		Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y	
		Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y	
SURV		Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y	
		Y	ECOG-ACRIN	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y	
SXQOL		Y	SWOG	S1600 Bladder,Radical Cystectomy Outcomes Nutrition	S1600	Y	
		Y	SWOG	S1614 HBV in Ca Pts, TAF vs SOC	S1614	Y	
		Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y	
		Y	ALLIANCE	A221505 Brst, Hypofractionated Post Mast Rad	A221505	Y	
		Y	ECOG-ACR	EA8171	EA8171		
		Y	ECOG-ACR	EA9161	EA9161		